2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2849

Pain and Functional Trajectories in Symptomatic Knee Osteoarthritis over a 12-Week Period of Non-Pharmacological Exercise Interventions
Abstract Number: 2850

Jakinibs Decrease Chronic Low Back Pain and Increase Function: A Proof of Concept Trial
Abstract Number: 2851

General and Abdominal Obesity As Risk Factors for Late-Life Mobility Limitation Among Women with Total Knee or Hip Replacement for Osteoarthritis
Abstract Number: 2852

Widespread Pain Prior to Total Knee Replacement (TKR) Is Associated with Increased Risk of No Clinical Improvement in Pain Among Women
Abstract Number: 2853

Is Frailty Associated with Adverse Events after Total Joint Arthroplasty?
Abstract Number: 2854

Optimizing Data Capture for Performance – Metrics Using Smartphone App Technology
Abstract Number: 2855

Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
Abstract Number: 2856

Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2857

Short and Long-Term Follow-up of Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis
Abstract Number: 2858

Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy
Abstract Number: 2859

Development of New Juvenile Arthritis Disease Activity Score Cut-Offs for Oligoarthritis and RF-Negative Polyarthritis from a Large Multinational Cohort of Children with Juvenile Idiopathic Arthritis
Abstract Number: 2860

Enthesitis-Related Arthritis: Axial -Pattern Is Associated with an Expansion of Peripheral Th17 Populations .
Abstract Number: 2861

Treat-to-Target in Rheumatoid Arthritis: What Level of Treatment Response Is Necessary By 3 Months in Order to Achieve the Treatment Target By 6 Months? Results from the Real Life NOR-DMARD Study
Abstract Number: 2862

Diverse Disease Activity Measures Demonstrate That the Routine Assessment of Patient Index Data with 3 Measures (Rapid-3) Assesses Only Non Inflammatory Components of Disease and Should Not be Utilized in a Treat to Target Strategy in Rheumatoid Arthritis
Abstract Number: 2863

Serum Proteomic Signatures Predict Relapse in Rheumatoid Arthritis Patients Undergoing DMARD Withdrawal

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].